Regorafenib hydrate is a hydrate that is the monohydrate form of anhydrous regorafenib. Used for for the treatment of metastatic colorectal cancer in patients who have previously received chemotherapy, anti-EGFR or anti-VEGF therapy. Among its listed roles, it functions as a antineoplastic agent, a tyrosine kinase inhibitor and a hepatotoxic agent. It includes a regorafenib. It is grouped under the following drug class(es): Antineoplastic agents, Kinase inhibitors and VEGF inhibitors. Its therapeutic use is listed as antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Regorafenib hydrate and Stivarga (TN). Its PubChem CID is 24768591.
Regorafenib monohydrate
| CAS No | 1019206-88-2 |
|---|---|
| Molecular Formula | C21H17ClF4N4O4 |
| Molecular Weight | 500.8 g/mol |
| Synonyms | 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide;hydrate |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Regorafenib hydrate is a hydrate that is the monohydrate form of anhydrous regorafenib. Used for for the treatment of metastatic colorectal cancer in patients who have previously received chemotherapy, anti-EGFR or anti-VEGF therapy.
The listed CAS number is 1019206-88-2.
The listed molecular formula is C21H17ClF4N4O4.
The listed molecular weight is 500.8 g/mol.
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide;hydrate.
The source lists Regorafenib hydrate and Stivarga (TN).